A Study of CAR-T Cells in Subjects With Autoimmune Diseases

This is a single center, one-arm, open label study aiming to evaluate the safety and efficacy of CAR-T cells therapy in subjects with autoimmune diseases.

Key Inclusion Criteria:

• Male or female, between 18 and 65 years old;
• Diagnosed with Autoimmune Diseases, such as Systemic Lupus Erythematosus, Systemic Sclerosis, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sjögren's Syndrome, Antiphospholipid Syndrome, Immune Thrombocytopenia, Pemphigus；
• Good organ functions;
• Subjects must understand and personally, voluntarily sign and date an informed consent.

Key Exclusion Criteria:

• Had or has active malignancy;
• Patients who have previously received CD19-targeted drugs, or CAR-T therapy, or any other gene therapy products;
• Combined with other autoimmune disease that needs systemic treatment or therapy;
• Pregnant or lactating women;
• Has other factors that deemed not suitable by investigator.